Trials / Completed
CompletedNCT00664222
Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)
Effects of Spironolactone on Insulin Resistance in Patients With Chronic Heart Failure
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Tottori University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.
Detailed description
Diuretics is useful in CHF patients. On the other hand, they deteriorate glucose metabolism. Therefore, the purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | spironolactone + furosemide | spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks |
Timeline
- Start date
- 2004-01-01
- Completion
- 2005-12-01
- First posted
- 2008-04-22
- Last updated
- 2008-04-22
Source: ClinicalTrials.gov record NCT00664222. Inclusion in this directory is not an endorsement.